Crystalline forms of a dipeptidyl peptidase-IV inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9181262
APP PUB NO 20150099891A1
SERIAL NO

14507001

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Novel crystalline forms of (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine are potent inhibitors of dipeptidyl peptidase-IV and are useful for the treatment of non-insulin dependent (Type 2) diabetes mellitus. The invention also relates to pharmaceutical compositions containing these novel forms, processes to prepare these forms and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MERCK SHARP & DOHME LLC126 EAST LINCOLN AVENUE RAHWAY NJ 07065

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Arroyo, Itzia Z Union, US 2 1
Biftu, Tesfaye Freehold, US 86 757
Chen, Ping Edison, US 557 5577
Krueger, Davida Brooklyn, US 2 1
Moment, Aaron J Scotch Plains, US 4 3
Sheen, Faye Hoddesdon, GB 6 11
Zhang, Yanfeng Panan, CN 177 515

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 10, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00